FutureFuel reported a third-quarter loss of $0.19 per share on revenue of $104.68 million. Revenue rose 361.3% from a year ago, and the loss narrowed from $0.21, which Earnings Whispers calculates as 9.5% earnings growth. No consensus estimate or whisper number was available. The year-over-year comparison is the friendliest way to read this quarter, and it is not the most useful one. In the second quarter, FutureFuel earned $11.4 million and generated $11.8 million of adjusted EBITDA. In the third quarter, the net result swung to an $8.4 million loss and adjusted EBITDA fell to negative $4.9 million. That is the central tension: record-level top-line activity coincided with a sharp sequential reversal in profitability and cash.

The quality of the revenue growth deserves scrutiny. Biofuels drove nearly all of it, with segment revenue reaching $87.8 million, up from $52.9 million in Q2 and $7.1 million a year ago. Plant utilization climbed to 83% from 56% in Q2. Yet the segment posted a $9.8 million gross loss because record-high soybean oil and fat costs absorbed the gains from volume and pricing. Consolidated results also carried $8.7 million of net derivative losses. Management says part of the hit is a timing issue. It expects to recover $2.3 million of hedging losses tied to unsold inventory and to recognize $1.5 million from RINs generated in Q3, for roughly $3.8 million of Q4 benefit. Even after that adjustment, biodiesel ran at full tilt and still did not make money in the quarter.

Chemicals delivered the more encouraging underlying story, despite the visible damage. Segment revenue fell to $16.9 million from $25.8 million in Q2, and utilization collapsed to 32% from 65% in Q2. Two problems drove the decline:

• Customer A paused orders to rebalance inventory, prompting the company to pull forward a turnaround.
• Customer B's planned turnaround ran long.

Together these cost about $4.3 million of adjusted EBITDA. Even so, chemical revenue grew 8.6% from a year ago. Performance chemicals more than tripled to $3.6 million on a new customer and glycerin sales, and segment gross profit was $4.4 million versus a $4.0 million loss a year earlier. Management says chemicals production has returned to normalized rates and expects Q4 utilization to exceed prior-year levels.

The forward catalyst list is longer and more concrete than it was a quarter ago:

• **Biodiesel orders:** More than 90% of Q4 biodiesel capacity was booked by early November.
• **Regulation:** A RIN-equivalence change effective January 1, 2027, is expected to narrow renewable diesel's advantage over biodiesel.
• **New customer:** A large European chemicals company reshoring production is slated to begin batches in Q1 2027 and reach full rates by mid-2027.
• **Glycerin refining:** The project requires less than $1 million of capex and is framed as a $5 million to $10 million annual profit opportunity beginning in 2027.
• **Customer A investment:** The customer's $41 million funded investment supports a rise in methacrylate utilization from about 50% to about 70% next year.

The press release guides to roughly $7 million of Q4 adjusted EBITDA, says positive full-year adjusted EBITDA is anticipated, and adds that no major maintenance is planned through Q1 2027. That Q4 figure would only bring the year to about breakeven, against a nine-month adjusted EBITDA loss of $6.9 million. It also leaves little room for further feedstock or customer surprises. On the call, management did not explicitly reaffirm the full-year target, so the written guidance appears firmer than the spoken commitment.

Bears have legitimate ammunition on the balance sheet. Third-quarter operating cash flow was negative $10.3 million, versus positive $18.8 million in Q2. Cash fell to $21.3 million from $34.3 million at midyear and from $51.3 million at the start of the year. Accounts receivable and inventory rose as biodiesel volumes expanded, absorbing working capital. The $35 million revolver remains undrawn, which provides a cushion. However, management said on the call that buybacks and dividend increases are deferred until cash is rebuilt to $50 million. That marks a meaningful shift in capital-return posture for a company that has historically leaned on shareholder distributions.

Current sentiment and price readings were not available, which limits what can be said about how the market is digesting the report. For reference, shares opened at $6.59 after the August report, well above the current 200-day moving average of $4.64. That gap shows how much optimism the Q2 profit print had built into expectations. The third quarter tested that optimism rather than validating it.

The bottom line is that FutureFuel's year-over-year numbers flatter a quarter that reversed the Q2 profit recovery and drained cash. The company still assembled a credible list of 2027 drivers. The investment case now rests on execution in Q4: normalized chemicals volumes, roughly $7 million of adjusted EBITDA, the derivative and RIN recoveries, and a halt to the cash decline. Until those show up in reported results, the growth story remains a forecast rather than a demonstrated turnaround.